Clinical trial
Intravitreal Ranibizumab Treatment of Central Serous Chorioretinopathy
NCT00403325 · Vitreous -Retina- Macula Consultants of New York, Other · Completed
Key facts
| NCT number | NCT00403325 |
|---|---|
| Title | Intravitreal Ranibizumab Treatment of Central Serous Chorioretinopathy |
| Official title | Phase I Study of Intravitreally Administered Ranibizumab in Subjects With Unresolving CSC and Subfoveal Fluid. |
| Lead sponsor | Vitreous -Retina- Macula Consultants of New York, Other |
| Collaborators | Genentech, Inc. Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Central Serous Chorioretinopathy |
| Intervention type | Drug |
| Interventions | rhuFab V2 [ranibizumab] ( Lucentis ) |
| Enrollment | 9 |
| Start date | Aug 1, 2006 |
| First posted | Nov 23, 2006 |
| Last update posted | Nov 3, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: